236 related articles for article (PubMed ID: 11193245)
1. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
Heikkinen J; Vaheri R; Kainulainen P; Timonen U
Osteoporos Int; 2000; 11(11):929-37. PubMed ID: 11193245
[TBL] [Abstract][Full Text] [Related]
2. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
4. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
5. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women.
Sun A; Lin S; Yu W; Qin M; Chen F; Zhang Y; Wei Y; de Lignieres B
Chin Med J (Engl); 2002 Dec; 115(12):1790-5. PubMed ID: 12622925
[TBL] [Abstract][Full Text] [Related]
7. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
Rees MC; Kuhl H; Engelstein M; Mattila L; Mäenpää J; Mustonen M;
Climacteric; 2004 Mar; 7(1):23-32. PubMed ID: 15259280
[TBL] [Abstract][Full Text] [Related]
8. A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women.
Heikkinen J; Vaheri R; Haapalahti J; Timonen U
Menopause Int; 2008 Jun; 14(2):70-7. PubMed ID: 18519268
[TBL] [Abstract][Full Text] [Related]
9. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen.
Mattsson LA; Skouby SO; Heikkinen J; Vaheri R; Mäenpää J; Timonen U
Climacteric; 2004 Mar; 7(1):59-69. PubMed ID: 15259284
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
11. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
12. [Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women].
Sun A; Lin S; Wei Y
Zhonghua Fu Chan Ke Za Zhi; 2001 Jun; 36(6):348-51. PubMed ID: 11783133
[TBL] [Abstract][Full Text] [Related]
13. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
14. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
Saure A; Planellas J; Poulsen HK; Jaszczak P
Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the dose of hormone replacement therapy.
Rice VM
Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
19. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
20. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
